Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions

Overview of attention for article published in Breast Cancer Research, August 2021

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (90th percentile)
High Attention Score compared to outputs of the same age and source (90th percentile)

Mentioned by

news: 2 news outlets

twitter: 9 X users

Readers on

mendeley: 170 Mendeley

So far, Altmetric has seen 2 news stories from 2 outlets.

High anti-tumor activity of a novel alpha-fetoprotein-maytansinoid conjugate targeting alpha-fetoprotein receptors in colorectal cancer xenograft model

Cancer Cell International, 05 Apr 2023

Abstract The alpha-fetoprotein receptor (AFPR) is a novel target for cancer therapeutics.

Next-Generation Antibody-Drug Conjugates Make Their Mark in Breast Cancer

OncLive, 02 Mar 2022

In 2013, ado-trastuzumab emtansine (T-DM1; Kadcyla) gained FDA approval for the treatment of patients with HER2-positive…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.